Global pharmaceutical company Novo Nordisk launches a new prescription-based treatment for individuals struggling with obesity. Wegovy—the brand name of semaglutide—is a once-weekly injectable medication that mimics glucagon-like peptide-1 (GLP-1), a hormone that is responsible for regulating appetite and blood sugar produced by the body. The drug helps individuals feel fuller for longer periods, reducing cravings and supporting sustained weight management.